Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $10.00

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Free Report) has been assigned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

ZNTL has been the subject of several research reports. Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th.

Get Our Latest Analysis on ZNTL

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Decheng Capital LLC raised its stake in shares of Zentalis Pharmaceuticals by 46.2% during the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after acquiring an additional 970,859 shares in the last quarter. Verition Fund Management LLC increased its stake in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares in the last quarter. Primecap Management Co. CA increased its stake in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after purchasing an additional 265,690 shares in the last quarter. Renaissance Technologies LLC increased its stake in Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares in the last quarter. Finally, GSA Capital Partners LLP increased its stake in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $2.26 on Friday. The stock has a market cap of $161.06 million, a price-to-earnings ratio of -0.91 and a beta of 1.86. Zentalis Pharmaceuticals has a 1 year low of $2.16 and a 1 year high of $18.07. The firm has a 50-day moving average of $3.11 and a two-hundred day moving average of $3.36.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. Research analysts expect that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

(Get Free Report

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Further Reading

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.